Tags: ,

Transasia Bio Medicals Ltd awarded ISO 13485
Transasia Bio Medicals Ltd awarded ISO 13485

Transasia Bio-Medicals Ltd, leader in the Clinical Diagnostics Segment across the Indian healthcare sector, which aids in diagnosing life threatening diseases faced by the humankind such as, AIDS, Tuberculosis, Cancer and Diabetes etc. has been awarded ISO 13485 (Quality Management Systems for Medical Devices) by UL India, a certifying body to foster quality assurance and improvement.

India and France to cooperate in the health sector
India and France to cooperate in the health sector

Union Health Minister, Dr. Anbumani Ramadoss, currently on an official visit to France, discussed cooperation in certain fields such as Medical Research, Biotechnology, Development of vaccine, Promotion of Indian Systems of medicines and cooperation between ICMR and INSERM of France

Global Alliance of IT Giants Powers Cancer Research
Global Alliance of IT Giants Powers Cancer Research

[This article was published in the December 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

Melbourne Branch of the Ludwig Institute for Cancer Research had researchers working across several labs using isolated computing systems that struggled to process the huge amounts of raw data generated. Microsoft worked with partners Dell and Intel, significantly reducing data processing times and simplifying and centralising management of the Institute�s computing environment.

Sound with a Sight TECHNOLOGY TRENDS – Ultrasound in Medical Imaging
Sound with a Sight TECHNOLOGY TRENDS – Ultrasound in Medical Imaging

[This article was published in the December 2007 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

Being one of the most widely used diagnostic tools in modern medicine, ultrasound-based electronic devices are increasingly used to harmlessly reveal the inner structure of human body. The technique, widely known as �ultrasonography� provides high quality visualisation of muscles, tendons, and internal organs, their size, structure and any pathological lesions with real time tomographic images.

NPIL, Merck in research deal for cancer drugs
NPIL, Merck in research deal for cancer drugs

Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.

whatsapp--v1